Patrick C. Hines

Radiology
97 West Parkway
Pompton Plains, NJ 07444

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.

crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.

Journal: Blood. Red cells & iron
Published: August 30, 2026

Acute pain in pediatric patients with SCD without chronic pain is associated with elevated VCAM-1 and P-selectin adhesion.

Acute pain in pediatric patients with SCD without chronic pain is associated with elevated VCAM-1 and P-selectin adhesion.

Journal: Blood vessels, thrombosis & hemostasis
Published: April 11, 2025

Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologies.

Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologies.

Journal: Lab on a chip
Published: March 15, 2024

Longitudinal assessment of adhesion to vascular cell adhesion molecule-1 at steady state and during vaso-occlusive crises in sickle cell disease.

Longitudinal assessment of adhesion to vascular cell adhesion molecule-1 at steady state and during vaso-occlusive crises in sickle cell disease.

Journal: British journal of haematology
Published: May 30, 2021

GBT1118, a voxelotor analog, protects red blood cells from damage during severe hypoxia.

GBT1118, a voxelotor analog, protects red blood cells from damage during severe hypoxia.

Journal: American journal of translational research
Published: April 19, 2021

Flow adhesion of whole blood to P-selectin: a prognostic biomarker for vaso-occlusive crisis in sickle cell disease.

Flow adhesion of whole blood to P-selectin: a prognostic biomarker for vaso-occlusive crisis in sickle cell disease.

Journal: British journal of haematology
Published: March 29, 2021

Can red blood cell function assays assess response to red cell-modifying therapies?

Can red blood cell function assays assess response to red cell-modifying therapies?

Journal: Clinical hemorheology and microcirculation
Published: January 18, 2021

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers.

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers.

Journal: Blood
Published: March 30, 2020

Cross-sectional analysis of adhesion in individuals with sickle cell disease using a standardized whole blood adhesion bioassay to VCAM-1.

Cross-sectional analysis of adhesion in individuals with sickle cell disease using a standardized whole blood adhesion bioassay to VCAM-1.

Journal: Blood cells, molecules & diseases
Published: September 23, 2019

Sevuparin blocks sickle blood cell adhesion and sickle-leucocyte rolling on immobilized L-selectin in a dose dependent manner.

Sevuparin blocks sickle blood cell adhesion and sickle-leucocyte rolling on immobilized L-selectin in a dose dependent manner.

Journal: British journal of haematology
Published: May 17, 2018

Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay.

Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay.

Journal: British journal of haematology
Published: June 25, 2016

VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.

VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.

Journal: British journal of haematology
Published: December 15, 2015
Showing 1-12 of 16

Last Updated: 09/26/2026